Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.

Pfizer

Status and phase: Terminated; Phase 4

Conditions: Parkinson Disease

Treatments: Drug: controlled-release levodopa / carbidopa; Drug: cabergoline

Study type: Interventional

Funder types: Industry

Identifiers

NCT00174239

A7231001

Details and patient eligibility

About

The study will assess the relative benefit of cabergoline vs carbidopa/levodopa therapy in treating nighttime problems of Parkinson Disease.

Full description

The trial was terminated prematurely June 26, 2005 due to the inability to re-supply study drug for the planned number of subjects. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Idiopathic Parkinson Disease
• Must be experiencing sleep akinesia

Exclusion criteria

• Current treatment with other dopamine agonists
• Nocturnal hallucinations
• Dementia

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind